ReviewInternational journal of chronic obstructive pulmonary disease2026
Type 2 Diabetes Mellitus and Chronic Obstructive Pulmonary Disease - from Pathophysiology to Effective Management Overview.
Review in International journal of chronic obstructive pulmonary disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease (COPD) are two chronic conditions with significant global impact and high incidence, frequently occurring as comorbidities. This article analyzes the particularities of pathophysiological, genetic, and epigenetic interactions, as well as the therapeutic implications in patients with both conditions. Additionally, the clinical management of these patients is investigated in correlation with updated international guidelines, such as the Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2026 and the American Diabetes Association (ADA) 2026. The importance of rigorous monitoring, personalized treatment, and the use of modern therapies with proven benefits-including sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide-1 (GLP-1) receptor agonists-is highlighted. The conclusion emphasizes the necessity of an integrated, multidisciplinary approach aimed at preventing complications, reducing cardiovascular risk, and improving the quality of life in comorbid patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.